SEARCHNARRATIVE_REVIEWgastroenterology, hepatology

narrative_review·gastroenterology, hepatology, primary_care, infectious_disease, rheumatology, neurology·PMC10132719

Understanding Our Tests: Hydrogen-Methane Breath Testing to Diagnose Small Intestinal Bacterial Overgrowth

Clinical and Translational Gastroenterology · 2 authors, 1 centre

AI SUMMARY

FIDELITY 100%

POPULATIONPatients suspected of having small intestinal bacterial overgrowth (SIBO), including those with IBS, celiac disease, Roux-en-Y gastric bypass, scleroderma, Parkinson's disease, liver disease, IBD, chronic pancreatitis, and older community populations.

INTERVENTIONHydrogen-methane breath testing using glucose or lactulose substrates, with measurement of exhaled hydrogen and methane gases.

COMPARISONJejunal aspirate culture as the gold standard reference test; also compared against clinical symptom predictors and alternative diagnostic approaches (e.g., empiric antibiotic trials, small bowel aspirates).

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

Hydrogen-methane breath testing is a widely used, noninvasive tool for diagnosing small intestinal bacterial overgrowth (SIBO), though its accuracy is moderate and influenced by patient factors, test substrate choice, and pretest probability. Glucose breath tests have better diagnostic performance (pooled sensitivity 54%, specificity 83%) than lactulose tests (sensitivity 42%, specificity 71%) when compared against jejunal aspirate cultures. Clinicians should integrate pretest probability estimates from high-risk populations (e.g., IBS, Roux-en-Y, scleroderma) with likelihood ratios to guide clinical decisions, and consider empiric antibiotic therapy when pretest probability is very high.

Full summary

4,583 CHARS

**Background:** Small intestinal bacterial overgrowth (SIBO) is increasingly recognized as a driver of common gastrointestinal symptoms including diarrhea, bloating, abdominal pain, and constipation. The gold standard diagnostic test—direct culture of small intestinal aspirates—is invasive, costly, and technically challenging. Hydrogen-methane breath testing has emerged as a noninvasive, inexpensive alternative, but its clinical application remains nuanced. This narrative review provides a comprehensive overview of breath testing paradigms, including indications, test administration, factors influencing results, performance characteristics, and integration into clinical decision-making.

**Methods:** The authors searched PubMed from inception through January 20, 2023, using keywords and MeSH terms without restrictions. For diagnostic accuracy, studies using jejunal aspirates as the gold standard were included. For prevalence estimates, English-language studies (systematic reviews, RCTs, cohort, case-control, or cross-sectional) with ≥100 adult patients using breath tests or small bowel aspirates were included. Studies had to include a control group. Systematic reviews with between-study heterogeneity (I²) ≥90% were excluded. Data extraction was performed independently by both authors with excellent agreement (Cohen kappa >0.80). Statistical calculations used Stata 13.1.

**Key Results:** - **Test performance (vs jejunal aspirates):** Glucose breath test (14 studies, 668 patients): pooled sensitivity 54% (48%–61%), specificity 83% (79%–87%), positive likelihood ratio (PLR) 2.45 (1.51–3.97), negative likelihood ratio (NLR) 0.60 (0.45–0.80), diagnostic odds ratio (DOR) 5.17 (2.42–11.05), area under the SROC curve 0.7418. Lactulose breath test (4 studies, 214 patients): pooled sensitivity 42% (32%–53%), specificity 71% (62%–78%), PLR 1.30 (0.77–2.22), NLR 0.79 (0.57–1.08), DOR 1.77 (0.72–4.37), AUC 0.5582. - **SIBO prevalence in high-risk populations:** IBS: 35.5% by mixed breath tests (controls 29.7%); Roux-en-Y gastric bypass: 73.4% by glucose breath test (symptomatic controls 36%); Parkinson's disease: 46% by mixed breath tests; liver disease: 35.8% by mixed breath tests (controls 8.0%); systemic sclerosis: 34% by breath tests; IBD: 22.3% by mixed breath tests (Crohn's 25.4%, UC 14.3%); chronic pancreatitis: 38.6% by mixed breath tests (controls 9.9%); celiac disease: 18.3% by breath tests; functional dyspepsia: 19.4% by duodenal aspirate culture (>10³ cfu/mL); older community (>61 yr): 15.6% by glucose breath test (controls 5.9%). - **Methane/IMO prevalence:** IBS total 20.0% (IBS-C 37.7%, IBS-D 12.4%, IBS-mixed 24.3%); IBD total 7.4% (Crohn's 5.3%, UC 20.2%); controls 23.5%. - **Symptom-based predictors:** Diarrhea had the best PLR (3.00) for a positive breath test, both as a baseline symptom and when occurring during the test. Other symptoms (gas, bloating, abdominal pain, distension) had PLRs ≤0.70. In patients with RYGB, antibiotic response rates were 78.3% in true-positive breath test groups vs 33.3% in false-positive groups (P=0.03). - **Test protocols:** North American Consensus guidelines define positive as hydrogen rise ≥20 ppm from baseline by 90 minutes, or methane ≥10 ppm at any time. Glucose 75 g is preferred over 50 g; lactulose 10 g is an alternative. The North American protocol yielded higher positivity rates (39.5%) vs modified Rome protocol (29.7%, P<0.001).

**Clinical Implications:** Breath testing is a moderately good diagnostic tool for SIBO, with glucose substrates outperforming lactulose. The test is most useful in populations with intermediate pretest probability (e.g., 20%–50%), where a positive result can shift posttest probability meaningfully (e.g., from 28% to 48.8% in symptomatic celiac disease). In very high pretest probability populations (e.g., RYGB with diarrhea, pretest probability 73.4% rising to 89.2% with diarrhea as a symptom), empiric antibiotic therapy may be preferred over breath testing. Methane-predominant IMO is associated with constipation and may require combination antibiotic therapy (rifaximin + neomycin). The Fagan nomogram is recommended for integrating pretest probability with likelihood ratios. Key limitations include the need for strict dietary preparation, medication cessation (antibiotics for 4 weeks, prokinetics/laxatives for 1 week), and consideration of orocecal transit time in patients with dysmotility. Future research should explore hydrogen sulfide measurement, gradations of test positivity, and improved standardization across centers.

PICO

PPOPULATION

Patients suspected of having small intestinal bacterial overgrowth (SIBO), including those with IBS, celiac disease, Roux-en-Y gastric bypass, scleroderma, Parkinson's disease, liver disease, IBD, chronic pancreatitis, and older community populations.

IINTERVENTION

Hydrogen-methane breath testing using glucose or lactulose substrates, with measurement of exhaled hydrogen and methane gases.

OOUTCOME

Diagnostic accuracy (sensitivity, specificity, positive/negative likelihood ratios, diagnostic odds ratio, area under the SROC curve); prevalence of SIBO in various populations; symptom-based predictive values.

STUDY TYPE

narrative_review

SPECIALTY

gastroenterology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10132719

Understanding Our Tests: Hydrogen-Methane Breath Testing to Diagnose Small Intestinal Bacterial Overgrowth

Clinical and Translational Gastroenterology

READ THE FULL PAPER

ABSTRACT

There is increasing appreciation that small intestinal bacterial overgrowth (SIBO) drives many common gastrointestinal symptoms, including diarrhea, bloating, and abdominal pain. Breath testing via measurement of exhaled hydrogen and methane gases following ingestion of a readily metabolized carbohydrate has become an important noninvasive testing paradigm to help diagnose SIBO. However, because of a number of physiological and technical considerations, how and when to use breath testing in the diagnosis of SIBO remains a nuanced clinical decision. This narrative review provides a comprehensive overview of breath testing paradigms including the indications for testing, how to administer the test, and how patient factors influence breath testing results. We also explore the performance characteristics of breath testing (sensitivity, specificity, positive and negative predictive values, likelihood ratios, and diagnostic odds ratio). Additionally, we describe complementary and alternative tests for diagnosing SIBO. We discuss applications of breath testing for research. Current estimates of SIBO prevalence among commonly encountered high-risk populations are reviewed to provide pretest probability estimates under a variety of clinical situations. Finally, we discuss how to integrate breath test performance characteristics into clinical care decisions using clinical predictors and the Fagan nomogram.

CITATION EXPORT

Aylin Tansel, David J. Levinthal. Understanding Our Tests: Hydrogen-Methane Breath Testing to Diagnose Small Intestinal Bacterial Overgrowth. Clinical and Translational Gastroenterology. (2023). https://doi.org/10.14309/ctg.0000000000000567

AUTHORS

2 · 1 CENTRES

Aylin Tansel, David J. Levinthal

1Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, USA.